Astellas CEO Naoki Okamura is putting a “patient axis” operating model, a broader portfolio of strategic brands and a new generation of science to work in the company’s bid to return to record growth.
Commentary|Podcasts|August 22, 2025
The Rx for High-Performance Leadership: Cutting Through the Chaos
Author(s)Michael Christel
Ken Banta, founder and CEO of The Vanguard Network, reveals the mindsets and moves biopharma leaders need to not just endure—but rise above—the current age of industry disruption.
Advertisement
In a turbulent era for the life sciences, leadership demands clarity, resilience, and adaptability. In this candid podcast conversation with Pharm Exec, Ken Banta, founder and CEO of The Vanguard Network, shares high-level insights on what CEOs can do to thrive amid the disruption—from regulatory agility to cultural resilience. The corporate strategy expert and author of the new book Seeing Around Corners explains why the best leaders are the best learners—and how prioritization, honesty, and boldness will separate those who merely survive from those who shape the industry’s future.
Highlights of the interview include:
- Navigating a “new maze” at the FDA and its personality-driven complexities
- R&D bets shifting toward proven winners, leaving long-shot breakthroughs behind
- Building trust and culture through transparency in uncertain times
- The call for leaders to embrace continuous learning—from AI startups to lab bench innovators
Click below to listen. View/download the transcript
Advertisement
Related to this article
A passing FDA inspection tells pharma senior leadership very little about whether the next significant revenue vulnerability is already taking shape. But continuous, AI-enabled quality management maturity (QMM) has the potential to do so months before the issue reaches the realm of P&L.
AI does not end uncertainty in pharma strategy. Its value depends on how well leaders blend it with experience and evidence while keeping judgment human.
Thomas Appio has been named interim CEO of Bausch + Lomb, a move coinciding with an expected upward revision to the company’s full-year guidance.
Why hub vendor transitions fail — and the four questions every manufacturer should answer before signing with a new patient support program vendor.
MERGE's Pat McGloin on why pharma AI fails when strategy follows technology — and why the brilliant basics still have to come first.
Gilead and Vir Biotechnology strike a $1.87 billion T-cell engager collaboration, and Fox Rothschild’s Marc Wagner examines what slows manufacturers’ response to rising drug demand and how compounding pharmacies help fill the resulting gaps.
Experts warn prediction markets are exposing gaps in pharma vendor confidentiality agreements, Roche licenses Rona Therapeutics’ obesity RNAi candidate while Pfizer partners with Enodia Therapeutics on Sec61 inhibitors, and PaxSafe’s Mark Talens makes the case for acting on imperfect supply chain data.
Advertisement
Advertisement
Trending on PharmExec
1
AstraZeneca Taps insitro AI for MASH in Deal Worth Up to $1.5 Billion
2
The Impact That the Renewed Focus on Domestic Manufacturing Might Have on the Supply Chain
3
FDA Launches Rare Disease Framework Initiative
4
Pharmaceutical Executive Daily: Gilead Enters $1.87 Billion Collaboration and License Agreement with Vir Biotechnology
5